Cyclin-dependent-like kinase 5 (Cdkl5) gene mutations lead to an X-linked disorder that is characterized by infantile epileptic encephalopathy, developmental delay and hypotonia.
Introduction
Mutations in the X-linked Cdkl5 gene, encoding the cyclin-dependent-like kinase 5, are associated with the CDKL5 Deficiency Disorder (CDD) that is characterized by early-onset intractable seizures, severe intellectual disability, and motor impairment (1, 2) . Cdkl5 is strongly expressed in the central nervous system (CNS), particularly in neurons of the cortex and of the hippocampus (3) . Defective Cdkl5 impairs proper brain development, learning and memory, neuronal activity, including molecular processes related to neuronal depolarization and synapse formation (4) (5) (6) (7) . Cdkl5 is activated by neuronal activity and it has also been implicated both in the phosphorylation and interaction with nuclear as well as cytoplasmic proteins potentially modulating gene expression and cytoskeleton changes ultimately affecting neuronal activity and cell survival (2, 5, 8, 9) . Recently microtubule and centrosome-associated proteins have been identified as targets of Cdkl5 kinase activity, including MAP1S, EB2, ARHGEF2, CEP131 and DLG5, whose regulation is likely to affect axonal transport, outgrowth and synaptic plasticity (10, 11) .
CDD remains a disease without a cure, whose fundamental molecular and cellular mechanisms are still in need of much investigation and whose full clinical spectrum remains only partially
characterized. An important current limitation is that unlike patients, CDD mutant mice do not develop epilepsy (4, (12) (13) (14) . This makes the identification of Cdkl5-dependent mechanisms or potential treatments with an impact on the human phenotype very challenging. Here, we discovered that CDD patients and animal models display an impairment in nociception and that Cdkl5 is required for peripheral nociceptive signalling in dorsal root ganglia (DRG) neurons in mice and in induced pluripotent cell (iPS)-derived human nociceptors. Mechanistically, conditional deletion of Cdkl5 in DRG sensory neurons significantly impairs nociception, Cdkl5 controls peripheral nociception 4 phenocopying CDKL5 deficiency disorder in patients. Lastly, we discovered that Cdkl5 interacts with CaMKIIα to control outgrowth of sensory neurons as well as TRPV1-dependent signalling including in iPS-derived neurons from CDD patients. Together, these findings reveal a previously unrecognized role for Cdkl5 in nociception and they suggest an original peripheral regulatory mechanism for pain processing with implications for future therapeutic interventions in CDD.
Results

Alteration in nociception in CDD patients
In a recent effort to broadly characterise the clinical phenotype, variation and natural history of CDD, the International CDKL5 Database (ICDD) (https://www.cdkl5.com/cdkl5-internationalregistry-database/) was established. Analysis of this clinical data source allowed the identification of a previously unrecognised significant occurrence of alterations in pain perception. In fact, the database included responses to questions to caregivers about whether their child currently experiences alterations in pain perception.
Since nociception had not been characterized so far in CDD and it can be promptly clinically assessed in both humans and animal models, we decided that it deserved further investigation.
Patients were classified by age group and mutation type ( Table 1) . Classification of individual CDKL5 mutations was based on predicted structural and functional phenotypic consequences similar to the groupings used in a previous study (15) . In our analysis we have grouped together mutations leading to lack of functional protein and missense/in-frame mutations within catalytic domain and TEYmotif and compared them with mutations affecting the regulatory domains of Cdkl5 i.e. truncations after aa172. Binary regression with log link was used to estimate the relative risk of altered pain sensitivity including by age groups and mutation type ( Table 1) .
Cdkl5 controls peripheral nociception 5 We found that altered pain sensitivity in their children was reported by 53.0% (122/230) of caregivers. Amongst these a total of 57.4% (70/122) specifically reported decreased pain sensitivity, 19 .7% (24/122) specifically reported enhanced sensitivity and 22.9% (28/122) reported both. 202 caregivers provided specific responses including either reduced (70/202, 34 .7%) or enhanced nociception (24/202, 11 .9%) ( Table 1) . Amongst those who reported either reduced or enhanced pain sensitivity, a total of 74.4% (70/94) reported decreased and 25.5% (24/94) increased nociception. The likelihood of the response being specifically reduced pain perception was measured as risk ratio (RR) of reduced or enhanced pain sensitivity versus normal pain perception. As shown in Table 1 reduced pain perception was more likely to be reported than enhanced pain perception (RR 2.92, 95% CI 2.89,7.00; p<0.001). Compared with those aged two years or under, individuals aged six years and over were reported to have an increased likelihood of reduced sensitivity to pain (RR 2.74, 95% CI 1.36,5.53; p=0.005).
Moreover, compared with those with mutations in the Cdkl5 regulatory domain (truncations after aa172), those with a non-functional protein (including missense/in-frame mutations within catalytic domain and TEY motif) were also reported to have an increased likelihood of reduced sensitivity to pain (RR 1.63, 95% CI 0.87,3.06; p=0.124). Reduced was significantly more likely than enhanced pain perception at each age group (0-2 years old, (RR 3.00, 95% CI 1.28,7.06; p=0.012); 3-5 years old, (RR 2.67, 95% CI 1.04,6.81; p=0.040); 6+ years old, (RR 3.00, 95% CI 1.52,5.94; p=0.002) and for each gene mutation group studied (no functional protein, (RR 2.94, 95% CI 1.67,5.18; p<0.001); truncation after aa172, (RR 2.88, 95% CI 1.29,6.42; p=0.010).
Cdkl5 localizes to human and murine sensory neurons and is required for nociception
Since primary nociceptors are localized in the dorsal root ganglia, we initially investigated whether Cdkl5, so far localised to the CNS, was also expressed in the peripheral nervous system Cdkl5 controls peripheral nociception 6 in murine as well as human nociceptors. Surprisingly, immuno and co-immunohistochemistry studies in DRG revealed that Cdkl5 is indeed expressed and mainly found in the cytoplasm of small diameter DRG neurons ( Fig. 1A-C) , where the signal becomes detectable after the age of post-natal day P45 ( fig. S1A,B) . Around 90% of Cdkl5 positive neurons express the nociceptive markers CGRP or IB4 ( Fig. 1D-F) . The expression of Cdkl5 in murine DRG was confirmed by RT-PCR and immunoblotting ( fig. S1C,D) , where Cdkl5 was expressed although to a lower level compared to the brain.
Next, in order to find whether Cdkl5 was also expressed in human nociceptors, we differentiated iPSC obtained from human skin biopsies into nociceptors. After having confirmed the differentiation of iPSC by immunolabelling for βIII-Tubulin as neuronal and CGRP as nociceptor marker respectively ( fig. S2A-E) , we observed that Cdkl5 was indeed expressed in human nociceptors (Fig. 1G,H) .
In order to directly address whether the expression of Cdkl5 in DRG sensory neurons was required for nociception, we took advantage of the conditional deletion of Cdkl5 in sciatic DRG neurons by injecting an AAV5-creGFP or control GFP virus to the sciatic nerve of Cdkl5-floxed mice (12) ( Fig. 2A) . Since the cre-virus deletes Cdkl5 selectively in DRG neurons, the absence of Cdkl5 signal by immunoblotting strongly supports the selective neuronal expression in DRG ganglia as well as the efficiency of the deletion (Fig. 2B) . Cdkl5 conditionally deleted mice showed an increase in paw withdrawal latency and threshold in response to noxious hot temperature (Haargraves plantar test) and noxious mechanical stimulation (Von Frey) respectively ( Fig. 2C,E) . We performed the same functional tests in Cdkl5 mutant mice, an established mouse model of CDD carrying a nonsense mutation (stop codon) leading to deletion of Cdkl5-Ex6 (4). Here, we found a reduction in nociception compared to WT littermates that Cdkl5 controls peripheral nociception 7 phenocopied what observed in Cdkl5 conditionally deleted mice ( Fig. 2D,F) . Importantly, in Cdkl5 conditionally deleted mice additional sensory modalities were unaffected as indicated by the time-to-contact and the time-to-removal during the adhesive removal test (16) (Fig. 2G) .
Sensorimotor functions as assessed by the gridwalk task (17) , which evaluates motor coordination and proprioception were also unaltered ( Fig. 2H) , suggesting a selective role for CDKL5 in nociception. Together, these data suggest that Cdkl5 is required for physiological nociception that relies upon the expression of Cdkl5 in DRG neurons.
Cdkl5 controls the outgrowth of human and murine sensory neurons via a CaMKII-dependent mechanism
To investigate the signalling pathways involved in Cdkl5-dependent pain transmission, we decided to identify interactors of Cdkl5 in vivo. To this end, we performed immunoprecipitation of Cdkl5 from the murine cortex, where the kinase is highly enriched, followed by mass spectrometry of the eluate (Suppl. File 1 and fig. S3A ). Considering the normalized protein ratios of each immunoprecipitation experiment (n=6), we identified 23 proteins coimmunoprecipitating with Cdkl5 ( fig. S3B) . Interestingly, 74% of them correspond to genes associated with neuronal activity, neural development and epilepsy ( fig. S3C-F) , supporting the physiological relevance of our pool of interactors. Top ranked Cdkl5 co-immunoprecipitating proteins included CaMKIIα, putatively the strongest interactor of Cdkl5, and some proteins associated with the neuronal cytoskeleton, such as Myh10 (18), Tubb3 (19) and Dynch1h1 (20-23) ( fig. S3G ). The association with CaMKIIα suggests also a role for Cdkl5 in calciumdependent signalling, neuronal activity (24) and in cytoskeleton remodelling (25) (26) (27) (28) (29) (30) .
Previous immunohistochemical studies have found that CaMKII is expressed in DRG nociceptors (31) , where it plays a role in the regulation of neurite outgrowth (32) . In particular, Cdkl5 controls peripheral nociception 8 CaMKII is expressed in TRPV1-immunoreactive nociceptors, in both CGRP+ and IB4+ subpopulations, where it is required for capsaicin-mediated nociception via modulation of TRPV1; capsaicin stimulation of TRPV1 and calcium entry activate CaMKII that is in turn required to potentiate TRPV1 signalling (33, 34) . Hence, we hypothesised that Cdkl5 could be a partner of CaMKIIα in the regulation of pain both via modulation of cytoskeleton remodelling and nociception signalling pathways.
First, we examined by confocal microscopy the co-expression of Cdkl5, CaMKIIα and TRPV1 in DRG neurons and we found that they co-localize in most DRG neurons ( Fig. 2I-M) . Next, we confirmed, by co-immunoprecipitation and immunoblotting from brain extracts, that Cdkl5 does interact with CaMKIIα in vivo ( fig. S3H) . Similarly, co-immunoprecipitation experiments after overexpression of CDKL5 in HEK293 cells, or of its inactive kinase dead form CDKL5-K42R
and CaMKIIα, confirmed the interaction between the active form of CDKL5 and CaMKIIα. Importantly, no interaction was observed between CaMKIIα and CDKL5-K42R ( fig. S3I) , which showed lack of kinase activity in an in vitro kinase assay ( fig. S3J) , supporting the specificity of the findings. We finally established the molecular proximity between Cdkl5 and CaMKIIα in DRG neurons by using the Proximity Ligation Assay (Fig. 2N,O) , supporting the co-expression and co-immunoprecipitation data.
We next investigated whether Cdkl5-CaMKIIα signalling axis would be required for the outgrowth of DRG neuronal processes. Assessment of neurite outgrowth was carried out in both murine and human iPSC derived nociceptors from Cdkl5 null mice and CDKL5 deficiency disorder patients. We found that cultured DRG neurons from Cdkl5 mutant mice display impaired neurite outgrowth in CGRP positive neurons ( Fig. 3A,C) , and this is rescued to the WT levels by viral-mediated overexpression of CDKL5 ( Fig. 3E; fig. S4 ). On the contrary, outgrowth in proprioceptive parvalbumin positive neurons remained unaffected by Cdkl5 loss of function ( Fig. 3B,D) , indicating a specific role for Cdkl5 in nociceptors. Importantly, impaired neurite outgrowth was also observed in iPSC-derived nociceptive DRG neurons (CGRP+) obtained from skin biopsies of CDKL5 patients, compared with the respective isogenic controls ( Fig. 3F,G) . CGRP+ neurons represent 30-40% of WT and mutant DRG neurons and more than 90% of iPSC derived sensory neurons were βIII-Tubulin+ ( fig. S2D ). Capsaicin responding cells were ~60% of the KCl responding murine DRG cultured neurons, while they were more than 90% of the KCl responding iPSC derived neurons, both in mutant and isogenic cultures, indicating functionality of the nociceptors (fig, S2E) . Interestingly, we found that neurite outgrowth was impaired in neurons derived from patients carrying a Cdkl5 mutation compromising the kinase active site and the TEY motif, but not in neurons where only the terminal part of the Cdkl5 tail is lost ( Fig. 3H; Table 1 ).
Next, we asked whether CaMKII activity was required for Cdkl5-dependent neurite outgrowth.
Indeed, we found that DRG outgrowth was significantly impaired following administration of the specific CaMKII enzymatic inhibitor KN93, while its inert structural analog KN92 did not have an effect ( Fig. 4A,B) . Interestingly, KN93 did not further reduce outgrowth in Cdkl5 mutant cells ( Fig. 4A,B) , indicating that CDKL5 and CaMKII belong to the same signalling pathway. Importantly, CDKL5 overexpression rescued outgrowth defects in Cdkl5 mutant knockout DRG neurons, but this effect was blocked by KN93. These data together suggest that Cdkl5-dependent DRG outgrowth relies on CaMKII.
Since epidermal innervation is needed for proper nociception and it is a dynamic process requiring continuous cytoskeleton remodelling and outgrowth, we examined if Cdkl5 deficiency was associated with a defect in epidermal innervation.
Indeed, immunohistochemical analysis of skin innervation revealed impairment in epidermal but not dermal innervation in Cdkl5 mutant versus WT adult mice ( Fig. 5A-E) . We also measured epidermal innervation from the post-natal day 4 (P4) to adulthood (P70) and found that Cdkl5 mutant mice display deficient epidermal innervation only in adulthood (P70), and not at earlier stages (P4 or P16; Fig. 5B ). In support of these data, we found, by immunoblotting of skin lysates, that the specific neuronal and axonal proteins PGP9.5, CGRP and βIII-tubulin are reduced in Cdkl5 mutants as compared to WT adult mice ( Fig. 5F,G) . However, consistent with the selective reduction of nociceptive fibres in the epidermis of Cdkl5 mutant mice, the expression of these axonal proteins is not reduced in sciatic nerve lysates ( Fig. 5H ,I) or after immunostaining for CGRP ( Fig. 5J,K) , in Cdkl5 mutant mice.
Cdkl5 is required for TRPV1/CaMKII-dependent signalling and nociception in sensory neurons and in vivo
Since TRPV1 activity relies on CaMKII-dependent interaction and phosphorylation (33, 34) , we hypothesized that TRPV1 signalling might require Cdkl5. Therefore we aimed to address whether Cdkl5 and CaMKII regulate TRPV1-dependent calcium signalling after stimulation with the well-established ligand capsaicin, which activates nociception by engaging with its receptor TRPV1 (35) (36) (37) .
We used capsaicin as specific activator of TRPV1 and we measured calcium influx in iPS derived nociceptors to find that capsaicin-induced increase in calcium is impaired in neurons carrying CDKL5-mutations involving the kinase active domain (E55fsX74) and the TEY motif (G155fsX197) ( Fig. 4C) . Similarly, capsaicin-induced calcium responses were impaired in Cdkl5 mutant murine DRG explants and cultured neurons, where we established that overexpression of AAV9-CDKL5 rescued the defect in calcium response ( Fig. 4D,G) . When we blocked CaMKII signalling in cultured WT DRG neurons by using KN93, in contrast to its inert structural analog KN92, we observed, as expected, that KN93 inhibited the activation of TRPV1 after administration of capsaicin. Inhibition was similar to what observed in Cdkl5 mutant cells, where the CaMKII inhibitor did not further decrease calcium levels ( Fig. 4E) . Delivery of KN93 after overexpression of CDKL5 in Cdkl5 mutant DRG neurons blocked the rescue in calcium levels after capsaicin delivery ( Fig. 4F) . Together, these data confirm our initial hypothesis that CaMKII is required for Cdkl5-dependent calcium responses after capsaicin.
Finally, we hypothesized that capsaicin signalling would also be compromised in vivo leading to biochemical and behavioural impairments in Cdkl5 deficient mice. In line with this hypothesis, we found that both the licking behaviour and cell signalling response to intradermal injection of capsaicin were impaired in vivo in Cdkl5 -/y mutant mice and following conditional deletion of Cdkl5 specifically in sciatic DRG sensory neurons. In fact, the time spent licking the paw after injection of capsaicin (1µg) was significantly reduced both in Cdkl5 -/y mice and in AAV5-CRE vs AAV5-GFP treated Cdkl5-floxed mice ( Fig. 6A-C) . Consistently, five minutes after capsaicin injection, pCaMKIIα was upregulated in DRG in WT but not in Cdkl5 -/y mice, supporting a defective signalling response ( Fig. 6D-F) . We confirmed defective transmission of the stimulus in Cdkl5 -/y mice also to the dorsal horn of the spinal cord by measuring pERK1/2 expression, typically activated by capsaicin-TRPV1 signalling in lamina I-II of the dorsal horn (38) . Indeed, pERK1/2 was induced only in WT but not in Cdkl5 -/y mice following intradermal injection of capsaicin ( Fig. 6G-I) (39, 40) .
Discussion
Our data reveal a previously unknown function of Cdkl5 in the regulation of primary nociception in the peripheral nervous system as shown by impaired nociception following conditional Cdkl5 controls peripheral nociception 12 deletion of Cdkl5 in DRG sensory neurons. Specifically, we found that Cdkl5 is required for CaMKII-dependent TRPV1 signalling and outgrowth of sensory neurons in both CDD murine and human neurons. In vivo, in a CDD animal model, this translates into impaired capsaicindependent nociceptive signalling and behavioural responses as well as in reduced epidermal innervation.
The anatomical, mechanistic and functional data all together support the anamnestic evidence that over 34% of CDKL5 patients have defective nociception. In a much smaller percentage of patients with enhanced pain perception, cortical hyperexcitability, which is a typical feature of these patients, might lead to dysfunctional central processing of nociception. This might be in line with disorders affecting cognition and neuronal activity in the central nervous system such as ASD and Rett syndrome (RTT), where it has been proposed that altered pain sensitivity is related to a dysfunctional mode of cortical pain processing, rather than to defective primary peripheral nociception (41) (42) (43) (44) (45) . CDD and RTT are distinct diseases caused by mutations in separate independent genes, Cdkl5 and methyl CpG binding protein 2 (MeCP2) respectively.
However, in vitro data suggested that the two might interact (1, 46, 47) , although functional interaction in vivo remains unclear.
Recently, genes such as MeCP2 and Ca2+/calmodulin-dependent protein kinase IIα (CaMKIIα), which have been implicated in the pathogenesis of ASD (48) (49) (50) , and that are highly expressed in the CNS, have also been localized to the peripheral nervous system where they regulate sensory modalities (51, 52) . However, a role in nociception had not been described so far.
Limitations of our work include the need for future investigation into potential additional Cdkl5dependent mechanisms that might control nociception. Additionally, it is presently not known whether Cdkl5 plays a role in inflammatory or in traumatic painful conditions. In summary, the importance of these findings lies on the (i) identification of a previously unrecognized regulatory mechanism for nociception that relies on Cdkl5, the (ii) discovery of impaired nociception as a previously uncharacterized symptom in CDD and (iii) the usefulness of nociception as therapeutic outcome measure in animal models of CDD. Since animal models and carprophen (5 mg kg −1 ) were administered peri-operatively as analgesic. The experimenter was blind to the genotype of animals and to treatment given to each animal.
Epidermal innervation
Following euthanasia, the external skin of the mouse foot was sterilized with ethanol and a skin punch, 1 mm in diameter, was introduced perpendicularly to the surface of pad skin, rotated and advanced until reaching 1-2 mm depth (53) . The specimens were immediately fixed in 3% paraformaldehyde, 75mM Lysine hydrochloride (Sigma L5501), 2.2mg/ml Sodium Metaperiodate (Sigma S1878) for up to 24 hours at 4 °C, and then kept in a cryoprotective solution overnight. After fixation, the tissue was serially cut (sections of 50 µm in thickness, perpendicular to the dermis) using a freezing microtome. The slices were then treated with blocking solution for two hours at RT (PBS -Triton X-100 0.3% -Donkey Serum 10%) and exposed to different primary Abs. βIII-Tubulin (Abcam ab-18207) and Collagen IV (Sigma C1926) were the markers used to assess, respectively, the density of IENF and the basal lamina.
Using confocal microscopy (Leica TCS SP5 II or Zeiss LSM-780 inverted confocal microscope), individual IENF crossing the dermal-epidermal junction were counted and the intraepidermal network length was analyzed by using Neuron-J software (magnification X20) in at least three non-consecutive sections (54) . 
Murine DRG, Spinal Cord and Sciatic Nerve Immunohistochemistry
After euthanasia, the tissues were removed and fixed in 4%-PFA-PBS for up to 24 Cells were fixed with 4% PFA -4% sucrose and the immunocytochemistry was performed by incubating fixed cells with βIII-tubulin (Abcam ab18207) and CGRP (Abcam ab81887) antibodies at 4 °C overnight. This was followed by incubation with AlexaFluor-conjugated goat secondary antibodies according to standard protocols (Invitrogen). All cells were counterstained with Hoechst (Molecular Probes). 
Western Blot analysis of skin, brain, DRG and sciatic nerve lysates
RNA isolation and RT-PCR Analysis
Total RNA was isolated using the RNeasy Mini Kit ( . After 2 months, the animals were exposed to specific behavioural tests and then sacrificed, to evaluate the silencing of Cdkl5gene in sciatic DRGs by WB.
Mechanical Allodynia Test
Mechanical allodynia was quantified by measuring the hind paw withdrawal response to von Animals were allowed to habituate for 1 h before testing in order to allow an appropriate behavioural immobility.
Hargreaves' Test (Plantar Test)
Thermal hyperalgesia was assessed as previously reported by Hargreaves et al. Paw withdrawal latency in response to radiant heat was measured using the plantar test apparatus (Ugo Basile, Varese, Italy). Briefly, the mice were placed in methacrylate cylinders (20 cm high × 9 cm diameter) positioned on a glass surface. The heat source was positioned under the plantar surface of the hind paw and activated with a radiant light beam, intensity was chosen in preliminary studies to give baseline latencies from 8 to 9 s in control mice. A cut-off time of 15s was used to prevent tissue damage in the absence of response. The mean paw withdrawal latencies from both hind paws were determined from the average of five separate trials, taken at 2-min intervals to prevent thermal sensitization and behavioural disturbances. Animals were habituated to the environment for 1 h before the experiment to become quiet and to allow testing (56) .
Grid walk
Mice were allowed to run the grid walk (50 × 5 cm plastic grid (1 × 1 cm) placed between two vertical 40-cm-high wood blocks) three times per session. The total number of steps and missteps per run for each hindpaw was analyzed by a blinded investigator.
Adhesive removal
Small adhesive stimuli (6-mm round adhesive labels) were placed on both hindpaws of the mouse, the time to make first contact with both forepaws, as well as the time to completely remove the adhesive were recorded for each paw. Each mouse underwent three trials. All testing was performed by a blinded investigator, after a period of acclimatization.
Cdkl5 Immunoprecipitation
The cortex of three mice (P65) was removed and immediately lysed in lysis buffer (Tris-HCl 7. For each sample, 1mg of protein was treated for 30m with 500U Benzonase (E1014 Sigma) at 37°C, then exposed (overnight wheel, 4°C) to 1µg of Cdkl5-Ab (Sigma HPA002847) or 1µg
Rabbit IgG (Jackson 011000003 lot95014). Magnetic beads (40µl 50% Dynabeads Protein G 10003D, Life Technologies) were subsequently added to the samples, and the mixture was further incubated on the wheel for 2hrs at 4°C. The beads were washed three times (3x20m washes with lysis buffer, wheel 4°C) and proteins were eluted by boiling for 10 min in NuPage Sample Reducing Agent -DTT (30µl, Thermo-Fisher NP0009; 80°C) and loaded on a 8% SDS-PAGE or analyzed by Mass Spectrometry. 
Mass Spectrometry Sample Preparation
Mass Spectrometry Measurement and Data Analysis
Reversed-phase chromatography gradient (Buffer A: 
DuoLink Proximal ligation Assay
After blocking DRGs slices (50µm of thickness), from P65 C57Bl/6 Cdkl5 null mice and wildtype littermates with Duolink Blocking Solution, primary antibodies raised in two different species, specific for the two proteins of interest (rabbit-Cdkl5 Sigma HPA002847 and mouse-CaMKIIα Thermo-Fisher MA1-048), were added to the tissue samples (1:100) and incubated in a humidity chamber overnight at 4°C. After washing, according to the manufacturer protocol (PLA; Sigma DUO92101), the samples were then incubated with secondary antibodies coupled to oligonucleotides (proximity probes) for 1 hour at 37°C and exposed to the ligase for 30 minutes at 37°C; the DNA polymerase was lastly added for 100 minutes at 37°C. The slides were washed thereafter, mounted and analyzed at the Leica TCS SP5 II confocal microscope (63x magnification; 6 non-consecutive 38µm-sections from the entire DRG).
DRG culture
Adult DRGs were dissected and collected in Hank's Balanced Salt Solution (HBSS) on ice and digested according to standard procedures. Cultures were maintained in medium containing B27 and penicillin-streptomycin in DMEM:F12. Cells were plated on coated glass coverslips (0.01 mg ml −1 PDL) for 48-72 h, and fixed with 4% PFA-4% sucrose.
Immunocytochemistry was performed by incubating fixed cells with Cdkl5 (Sigma HPA002847), βIII-tubulin (abcam ab18207), CaMKIIα (Thermo-Fisher MA1-048), (abcam ab81887), Parvalbumin (abcam ab555), GFP (Thermo-Fisher A-6455), HA (abcam ab18181) antibodies at 4 °C overnight. This was followed by incubation with AlexaFluor-conjugated goat secondary antibodies according to standard protocols (Invitrogen). All cells were counterstained with Hoechst (Molecular Probes).
DRG explants
DRGs from adult WT and Cdkl5 null mice were isolated, plated on a culture dish and incubated 
DRG culture infection and treatments
WT and Cdkl5 null DRG-neurons seeded at a density of 5,000 cells/cm 2 were infected with AAV9 viral particles (AAV9-Ctrl-ss-pTR-CBh-GFP-stuffer; AAV9-ss-pTR-CBh-HA- Analysis of the levels of Phospho-CaMKIIα: 72 hrs after the treatment, the wells were fixed and processed with anti-phospho-Thr286-CaMKIIα (mouse, Thermo-Fisher MA1-047, 1:100) and beta-III-tubulin (rabbit, abcam ab18207, 1:500) antibodies, as previously described.
Neurite outgrowth analysis
Immunofluorescence was detected using a Nikon Eclipse-TE-2000U microscope at 20× magnification using a CDD camera (scMOS camera QImaging). Five fields per coverslip were included in the analysis. At least 30 cells per coverslip were measured. Total neurite length was measured and normalized to the number of cells. All analyses were performed blinded. Neurite analysis and measurements were performed using the Neuron-J plugin for ImageJ.
Image analysis for immunohistochemistry and immunocytochemistry
Photomicrographs were taken with Nikon Eclipse-TE-2000U microscope at 20× magnification.
Alternatively, for confocal imaging, a Leica TCS SP5 II or a Zeiss LSM-780 inverted microscope (z-stacks, slice spacing 1.65µm) were used at 20× or 63x magnification. DRG, spinal cord and sciatic nerve micrographs were processed with the software ImageJ: a constant fluorescence intensity threshold was set across each cell (or area) in control-tissues. On the basis of this threshold, for each cell (or area) in the samples, the intensity of pixels was calculated in each channel. This was done in triplicate and the investigator was blinded to the experimental group.
Single-cell calcium imaging
We assessed changes in the intracellular Ca2+ concentration ([Ca 2+ ] i ) using conventional ratiometric imaging in cultured DRG neurons isolated from WT and CDKL5 -/y mice. Briefly, after loading with 1µM Fura-2 (Invitrogen), the cells were exposed to capsaicin (500ng/ml) for Measurements were repeated at least in 3 independent cultures with analyzing ~100 (50 WT vs 50 CDKL5 -/y ) cells in each. Responses of CDKL5 -/y neurons were normalized to those of WT cells (62) .
Intradermal injection of capsaicin
Capsaicin (10 µl Sigma P0044-1x), sonicated (1 min) and then centrifugated at 10000g (5 min, 4°C). The protein concentration of the supernatant was determined by the Bradford method and the CDKL5 Immunoprecipitation was performed as described ("Cdkl5 Immunoprecipitation"). To confirm the overexpression of the kinases, the 5% of the supernatant was directly loaded on SDS-PAGE.
The kinase activity of CDKL5 was simultaneously verified using the supernatant of the lysate from plates overexpressing CDKL5 or its inactive form CDKL5-K42 (Kinase-Dead), exposed to Anti-Flag Beads (Sigma M2 Magnetic Beads; 2 hours, wheel 4°C). The beads were then washed three times (wheel 4°C, 20min) in Lysis Buffer, resuspended in Kinase Buffer-1x (Thermo-Fisher PV3189) and added to a mixture of 32P-ATP (1mM) and cold-ATP (1mM). After incubation (30 minutes at 30°C), the elution was performed by using Laemmli 6x (30 µl, 70°C, 3 min) and the samples were loaded on SDS-PAGE. The gel, fixed in methanol 2% (1 hour, RT), was dried (80°C, 2 hours) and exposed to an X-ray film for two days. differentiation into nociceptors (day 0, day 7 and 12). B, C. Graphs showing the percentage of CGRP and βIII-tubulin positive cells at the three different maturation stages (DAPI staining was used to establish the total number of cells). N: 3 independent experiments (E55fsX74, G155fsX197, S855X), Mean with SD, Two way ANOVA, Sidak's post-hoc, ****P<0.0001. D.
Statistics and reproducibility:
Graphs showing that a very high percentage of iPS derived nociceptors (differentiation day 12: E55fsX74, G155fsX197, S855X) display CGRP and βIII-tubulin co-expression. Almost the totality of differentiated neurons (βIII-tubulin+) are positive for the nociceptor specific marker CGRP. No difference was observed between mutant and isogenic control cells or between WT and Cdkl5 -/y murine DIV3 DRG cultures, where the percentage of βIII-tubulin and CGRP coexpressing neurons is about 40% of the total number. N: 3 independent experiments, Mean with SD, Multiple t-test, Two stage step-up method, P>0.05. E. Graphs showing the percentage of capsaicin responding cells compared to the total number of KCl responding DIV-42 iPS derived nociceptors (E55fsX74, G155fsX197, S855X) and WT murine DIV3 DRG neurons. Almost the totality of the iPS derived neurons respond to capsaicin equally between mutant neurons and their isogenic controls. Around 60-70% of DIV3 DRG neurons respond to capsaicin equally between WT and Cdkl5 -/y cultures. N: 3 independent experiments, Mean with SD, Multiple t-test, Two stage step-up method, P>0.05.
